Related Experiment Video
Updated: Jun 7, 2026

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
Published on: March 22, 2011
AAV vectors for cancer gene therapy
Myungeun Lee1, Jinhyun Park1, Ji Hoon Park1
1GeneCraft, Songpa-gu, Seoul, South Korea.
Adeno-associated virus (AAV) vector-based gene therapy offers a promising approach to overcome limitations in current cancer treatments. Advances in AAV technology are paving the way for its use in oncology, despite existing challenges.
Area of Science:
- Oncology
- Gene Therapy
- Biotechnology
Background:
- Current cancer therapies face limitations including resistance, toxicity, and variable efficacy.
- Adeno-associated virus (AAV) vectors present a safer, engineerable alternative for therapeutic development.
- AAV gene therapy is expanding from monogenic disorders to complex diseases like cancer.
Purpose of the Study:
- To review recent advancements in AAV-based gene therapy for cancer.
- To discuss the strategic considerations driving AAV vector development in oncology.
- To highlight progress in overcoming AAV-related challenges in cancer treatment.
Main Methods:
- Review of current literature on AAV vector technology in cancer.
- Analysis of strategic factors influencing AAV-based cancer therapy development.
- Discussion of biotechnological solutions for AAV limitations.
Main Results:
- AAV vectors show promise for overcoming limitations of conventional cancer therapies.
- Progress in vector technology and strategic planning supports AAV expansion into oncology.
- Biotechnological advances are addressing challenges like host immunity and packaging capacity.
Conclusions:
- AAV-based gene therapy is a rapidly advancing field with significant potential in oncology.
- Continued innovation in AAV technology and strategic development will facilitate its clinical implementation.
- AAV vectors are positioned as a next-generation therapeutic modality for cancer treatment.
More Related Videos
04:43Quantification of Adeno-Associated Viral Genomes in Purified Vector Samples by Digital Droplet Polymerase Chain Reaction
Published on: October 11, 2024
09:20Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus (AAV) Capsid Variants
Published on: October 18, 2022
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Gene Therapy
Gene Therapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...